Thus, in cancers where EGF and EGF receptors are involved, it is possible to target the ligand using chelating antibodies, to antagonize the receptor using blocking antibodies, to use specific antibodies to prevent dimerization of the receptor and to inhibit the catalytic activity of the receptor with small molecular inhibitors. The gene discussed is EGF; the disease is cancer.